Advances in Chemically Enhanced Peptide and Protein Therapeutics
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".
Deadline for manuscript submissions: closed (11 April 2024) | Viewed by 248
Special Issue Editors
Interests: inflammation; allergy; basic and clinical immunology
Special Issue Information
Dear Colleagues,
In pharmacology, new treatment strategies for decreasing collateral damage are continuously being developed to give patients the best possible quality of life over different diagnostics and treatments based on pharmaceutics. The development of multifunctional drugs has attracted tremendous attention over the years for peptides and proteins as therapeutic agents or complements to increase the capability, compatibility, and selectivity of treatments; these will eventually evolve into biotools for diagnostic and/or therapeutic applications in academia and pharmaceutical, biotechnological, or nanobiotechnological companies. Additionally, their excellent biotherapeutic capability to engage targets considered undruggable or extremely hard to target is what has led to these therapeutic agents representing the highest percentage of approved drugs last year.
However, in recent years, efforts have been focused on increasing stability, decreasing clearance, and decreasing proteolysis lability. These challenges can be overcome through chemical modification or “chemical enhancement”, such as conjugations to biomolecules, sequence modification, noncanonical amino acids, cyclization, nanomaterials, polymers, and other molecules.
This Special Issue titled “Advances in Chemically Enhanced Peptide and Protein Therapeutics” aims to collate as many original research articles and reviews as possible on pharmaceutical approaches applied to chemically enhanced peptides or proteins; proposal, synthesis, and characterization studies; in vitro and in vivo studies; and clinical trials. In addition, works aiming to increase knowledge on synthesizing various peptide- or protein-based formulations; characterization; diagnostics; treatments; and theragnosis are welcome.
We look forward to receiving your contributions.
Dr. Vincenzo Casolaro
Dr. Simon Guerrero
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- peptide therapeutics
- protein therapeutics
- peptide diagnosis
- protein diagnosis
- theragnostic
- drug delivery
- peptidomimetics
- antibody drugs
- peptide-conjugated
- protein-conjugated
